What is cutaquig® and what is it used for?
What is cutaquig?
Cutaquig belongs to a class of medicines called “human normal immunoglobulins”. Immunoglobulins are also known as antibodies and are proteins found in healthy people’s blood. Antibodies are part of the immunesystem (the body’s natural defense) and help your body to fight infections.
How Cutaquig works?
Cutaquig contains immunoglobulins that have been prepared from the blood of healthy people. The medicine works in exactly the same way as the immunoglobulins naturally present in your blood.
What is Cutaquig used for?
Cutaquig is used in patients who do not have enough antibodies to fight off infections and therefore tend to have frequent infections.
Regular administration of sufficient doses of Cutaquig can raise abnormally low immunoglobulin levels in your blood to normal levels (replacement therapy).
Cutaquig is prescribed to adults and children (aged 0-18 years) in the following situations:
Treatment of patients who are born with a reduced ability or inability to produce antibodies (primary immunodeficiency syndromes). These include but are not limited to conditions such as:
Low antibody levels (hypogammaglobulinaemia) or absence of antibodies (agammaglobulinaemia) in the blood
Combination of low antibody levels, frequent infections and inability to produce adequate amounts of antibodies after vaccination (common variable immunodeficiency)
Combination of low level or absence of antibodies and absence or nonfunctional immune cells (severe combined immunodeficiency)
Lack of certain antibody (immunoglobulin G) subclasses causing recurrent infections.
Treatment of patients with a certain type of blood cancer (chronic lymphocytic leukaemia), and recurrent infections where prophylactic antibiotics have failed or are contra-indicated.
Treatment of patients with cancer of the bone marrow (multiple myeloma), and recurrent infections.
Treatment of low antibody levels in patients before and after transplantation of bone marrow cells from another person (allogeneic haematopoietic stem cell transplantation – HSCT)
Cutaquig® European Patient Information Leaflet. March 2020.